South Korea-based Samsung Biologics has completed its acquisition of a biologics manufacturing facility in Rockville from GSK, marking its first manufacturing presence in the United States.
According to Samsung Biologics, the site includes two cGMP plants with a combined 60,000-liter capacity, supporting both clinical and commercial production. With the addition, the company’s total global manufacturing capacity has increased to 845,000 liters.
Under the agreement, Samsung Biologics will continue producing products for GSK at the Rockville site while expanding operations to support additional contract manufacturing needs. The company also plans to invest in expanding capacity and upgrading technologies, and more than 500 employees at the facility will transition to Samsung Biologics as part of the acquisition.
